当前位置: 首页 > 详情页

Primacy of the 3B Approach to Control Risk Factors for Cardiovascular Disease in Type 2 Diabetes Patients

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Peking Univ, Peoples Hosp, Dept Endocrinol & Metab, Beijing 100044, Peoples R China; [2]Peking Univ, Peoples Hosp, Dept Cardiol, Beijing 100044, Peoples R China; [3]Beijing 301 Mil Gen Hosp, Dept Endocrinol, Beijing, Peoples R China; [4]Sun Yat Sen Univ, Affiliated Hosp 3, Dept Endocrinol, Guangzhou 510275, Guangdong, Peoples R China; [5]Peking Univ, Affiliated Hosp 1, Dept Cardiol, Beijing 100044, Peoples R China; [6]Capital Med Univ, Beijing An Zhen Hosp, Dept Cardiol, Beijing, Peoples R China; [7]Fudan Univ, Huashan Hosp, Dept Nephrol, Shanghai 200433, Peoples R China; [8]Forth Mil Med Univ, Xi Jing Hosp, Dept Endocrinol, Xian, Peoples R China; [9]Sichuan Univ, West China Hosp, Dept Endocrinol, Chengdu 610064, Peoples R China; [10]Da Lian Med Univ, Affiliated Hosp, Dept Endocrinol, Dalian, Peoples R China; [11]VitalStrateg Res Inst, Berwyn, PA USA; [12]Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland; [13]SUNY Downstate Coll Med, Dept Med, Brooklyn, NY USA; [14]Peking Univ, Peoples Hosp, Dept Endocrinol & Metab, 11 Xi Zhi Men Nan Da Jie, Beijing 100044, Peoples R China
出处:
ISSN:

关键词: Cardiovascular risk factor China Dyslipidemia Hyperglycemia Hypertension Type 2 diabetes

摘要:
BACKGROUND: Individually, diabetes mellitus, hypertension, and dyslipidemia have been shown to increase the risk of cardiovascular disease. While traditional management of Type 2 diabetes has focused mainly on glycemic control, robust evidence supports the integration of hypertension and dyslipidemia management to reduce the risk of cardiovascular disease. The primary objective of this study was to assess the level of control of blood glucose, blood pressure, and blood lipids (3Bs) among patients with type 2 diabetes. An additional objective was to investigate the impact of hospital type, physician specialty, treatment pattern, and patient profile on clinical outcomes. METHODS: This was a cross-sectional, multicenter observational study. A nationally representative sample of outpatients with established type 2 diabetes were enrolled at hospitals representative of geographic regions, tiers, and physician specialties in China. Main clinical measurements were the levels of glycosylated hemoglobin (HbA1c), blood pressure, and total serum cholesterol in reference to target goals. RESULTS: A total of 25,817 adults with type 2 diabetes (mean age 62.6 years, 47% male) were enrolled at 104 hospitals. Seventy-two percent reported comorbid hypertension, dyslipidemia, or both. Patients with concurrent type 2 diabetes, hypertension, and dyslipidemia were 6 times more likely to report a prior history of cardiovascular disease compared with those with type 2 diabetes alone. The mean HbA1c level was 7.6%. While 47.7%, 28.4%, and 36.1% of patients achieved the individual target goals for control of blood glucose (HbA1c <7%), blood pressure (systolic blood pressure <130 mm Hg, diastolic blood pressure <80 mm Hg), and blood lipids (total cholesterol <4.5 mmol/L), respectively, only 5.6% achieved all 3 target goals. Lower body mass index (<24 kg/m(2)), no active smoking or drinking, higher education, and diabetes duration <5 years were independent predictors of better cardiovascular disease risk control. CONCLUSION: Achieving adequate control of risk factors for cardiovascular disease in patients with type 2 diabetes remains a clinical challenge. Interventions to achieve control of 3Bs coupled with modification of additional cardiovascular disease predictors are crucial for optimization of clinical outcomes in patients with type 2 diabetes. (c) 2013 Elsevier Inc. All rights reserved.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2012]版:
大类 | 2 区 医学
小类 | 2 区 医学:内科
最新[2023]版:
大类 | 3 区 医学
小类 | 2 区 医学:内科
JCR分区:
出版当年[2011]版:
Q1 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q1 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2011版] 出版当年五年平均 出版前一年[2010版] 出版后一年[2012版]

第一作者:
第一作者机构: [1]Peking Univ, Peoples Hosp, Dept Endocrinol & Metab, Beijing 100044, Peoples R China;
通讯作者:
通讯机构: [1]Peking Univ, Peoples Hosp, Dept Endocrinol & Metab, Beijing 100044, Peoples R China; [14]Peking Univ, Peoples Hosp, Dept Endocrinol & Metab, 11 Xi Zhi Men Nan Da Jie, Beijing 100044, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院